We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$21.7B
1-Year Est. Return
79.24%
This Fund
S&P 500
This Quarter
Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
(+14%)
Cap. Flow
-$3.46B
Cap. Flow
% of AUM
-15.95%
Top 10 Holdings %
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$166M |
| 2 |
Roivant Sciences
ROIV
|
+$137M |
| 3 |
Immunovant
IMVT
|
+$130M |
| 4 |
BridgeBio Pharma
BBIO
|
+$96.5M |
| 5 |
Baidu
BIDU
|
+$94.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$498M |
| 2 |
Amazon
AMZN
|
+$398M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$372M |
| 4 |
Aon
AON
|
+$365M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Miscellaneous | 21.83% |
| 3 | Communication Services | 8.41% |
| 4 | Technology | 5.7% |
| 5 | Financials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Capricor Therapeutics
CAPR
$540M
| – | – |
-41,000
| Closed | -$1.25M |
|
102
C4 Therapeutics
CCCC
$460M
| – | – |
-28,000
| Closed | -$73.6K |
|
103
Ceco Environmental
CECO
$4.35B
| – | – |
-234,000
| Closed | -$13.9M |
|
104
Celcuity
CELC
$4.72B
| – | – |
-4,000
| Closed | -$457K |
|
105
CG Oncology
CGON
$6.59B
| – | – |
-674,000
| Closed | -$44.1M |
|
106
Cummins
CMI
$75.1B
| – | – |
-9,000
| Closed | -$4.84M |
|
|
CNTA
107
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-4,809,000
| Closed | -$191M |
|
108
Cencora
COR
$64.4B
| – | – |
-1,000
| Closed | -$314K |
|
109
Walt Disney
DIS
$185B
| – | – |
-2,401,591
| Closed | -$231M |
|
110
Dianthus Therapeutics
DNTH
$6.03B
| – | – |
-836,000
| Closed | -$70.2M |
|
111
Dyne Therapeutics
DYN
$4.66B
| – | – |
-10,000
| Closed | -$181K |
|
112
Encompass Health
EHC
$12.1B
| – | – |
-3,000
| Closed | -$290K |
|
113
Entegris
ENTG
$20B
| – | – |
-45,500
| Closed | -$5.33M |
|
114
Erasca
ERAS
$5.69B
| – | – |
-18,000
| Closed | -$291K |
|
115
Evolent Health
EVH
$482M
| – | – |
-14,000
| Closed | -$31.9K |
|
|
FISV
116
Fiserv Inc
FISV
$28B
| – | – |
-86,000
| Closed | -$4.8M |
|
117
Flex
FLEX
$39.9B
| – | – |
-78,000
| Closed | -$5.11M |
|
|
FOLD
118
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-16,000
| Closed | -$231K |
|
119
FormFactor
FORM
$7.56B
| – | – |
-56,500
| Closed | -$5.48M |
|
120
GDS Holdings
GDS
$6.24B
| – | – |
-292,000
| Closed | -$11.8M |
|
121
GE HealthCare
GEHC
$31.5B
| – | – |
-3,000
| Closed | -$214K |
|
122
GlobalFoundries
GFS
$24.4B
| – | – |
-105,000
| Closed | -$4.67M |
|
123
Glaukos
GKOS
$10.6B
| – | – |
-2,600
| Closed | -$280K |
|
124
Globus Medical
GMED
$10.5B
| – | – |
-4,000
| Closed | -$345K |
|
|
125
Alphabet (Google) Class C
GOOG
$4.15T
| – | – |
-996,231
| Closed | -$286M |
|
Similar funds
BG
IC
OSAM
SA
BPA
CHP
PAG
ETC
Farallon Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Farallon Capital Management held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Farallon Capital Management withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Farallon Capital Management opened a new position in Parabilis Medicines Inc worth $64.8M.
- Farallon Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
- Farallon Capital Management added most to Boston Scientific in Q2 2026, an estimated $166M increase.
- Farallon Capital Management's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
- Farallon Capital Management fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
- Farallon Capital Management's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
- Farallon Capital Management opened 19 new positions and closed 105 in Q2 2026.
- Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $21.7B.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.